The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern

There is an urgent need for potent and selective antivirals against SARS-CoV-2. Pfizer developed PF-07321332 (PF-332), a potent inhibitor of the viral main protease (Mpro, 3CLpro) that can be dosed orally and that is in clinical development. We here report that PF-332 exerts equipotent in vitro acti...

Descripción completa

Detalles Bibliográficos
Autores principales: Abdelnabi, Rana, Foo, Caroline S., Jochmans, Dirk, Vangeel, Laura, De Jonghe, Steven, Augustijns, Patrick, Mols, Raf, Weynand, Birgit, Wattanakul, Thanaporn, Hoglund, Richard M., Tarning, Joel, Mowbray, Charles E., Sjö, Peter, Escudié, Fanny, Scandale, Ivan, Chatelain, Eric, Neyts, Johan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847371/
https://www.ncbi.nlm.nih.gov/pubmed/35169114
http://dx.doi.org/10.1038/s41467-022-28354-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847371/
https://www.ncbi.nlm.nih.gov/pubmed/35169114
http://dx.doi.org/10.1038/s41467-022-28354-0

Ejemplares similares